JPS6234725B2 - - Google Patents
Info
- Publication number
- JPS6234725B2 JPS6234725B2 JP55008730A JP873080A JPS6234725B2 JP S6234725 B2 JPS6234725 B2 JP S6234725B2 JP 55008730 A JP55008730 A JP 55008730A JP 873080 A JP873080 A JP 873080A JP S6234725 B2 JPS6234725 B2 JP S6234725B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antiviral agent
- staphylococcus
- pieces
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003443 antiviral agent Substances 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 241000191940 Staphylococcus Species 0.000 claims description 7
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 3
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims description 3
- 241000588653 Neisseria Species 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 241000193996 Streptococcus pyogenes Species 0.000 claims 2
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 description 13
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000002799 interferon inducing agent Substances 0.000 description 2
- 239000006402 liver broth Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000001973 thioglycolate broth Substances 0.000 description 1
- 239000007143 thioglycolate medium Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP873080A JPS56108716A (en) | 1980-01-30 | 1980-01-30 | Antiviral agent containing different kind dead cell mixture as effective component |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP873080A JPS56108716A (en) | 1980-01-30 | 1980-01-30 | Antiviral agent containing different kind dead cell mixture as effective component |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56108716A JPS56108716A (en) | 1981-08-28 |
| JPS6234725B2 true JPS6234725B2 (zh) | 1987-07-28 |
Family
ID=11701062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP873080A Granted JPS56108716A (en) | 1980-01-30 | 1980-01-30 | Antiviral agent containing different kind dead cell mixture as effective component |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56108716A (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19916085A1 (de) * | 1998-10-28 | 2000-05-04 | Sonntag Hans Guenther | Verfahren zur Herstellung eines antiviralen Mittels |
| NZ581806A (en) * | 2004-06-07 | 2011-10-28 | Qu Biolog Inc | Bacterial compositions for the treatment of cancer |
| US8501198B2 (en) | 2004-06-07 | 2013-08-06 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| US9107864B2 (en) | 2004-06-07 | 2015-08-18 | Qu Biologics Inc. | Tissue targeted antigenic activation of the immune response to treat cancers |
| EP3235506B1 (en) | 2010-07-26 | 2023-12-06 | Qu Biologics Inc. | Immunogenic anti-inflammatory compositions |
| US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
| CN106456740B (zh) | 2014-05-02 | 2021-06-08 | Qu生物制药公司 | 抗微生物免疫调节 |
-
1980
- 1980-01-30 JP JP873080A patent/JPS56108716A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56108716A (en) | 1981-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fishman | Antibody formation in vitro | |
| KR960003377B1 (ko) | 개량된 인터페론 요법 | |
| Storb et al. | Treatment of established human graft-versus-host disease by antithymocyte globulin | |
| CA1323564C (en) | Low dosage of interferon to enhance vaccine efficiency | |
| Spink et al. | Experimental studies on the significance of endotoxin in the pathogenesis of brucellosis | |
| KR960000395B1 (ko) | 혈소판감소증 치료제 | |
| Miller et al. | Streptomycin resistance of gonococci and meningococci | |
| EP0173241B1 (de) | Vakzine zur Behandlung der Harnwegsinfektionen | |
| US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
| Snell et al. | Interactions of gram-negative bacterial endotoxin with rabbit blood in vitro | |
| JPS6234725B2 (zh) | ||
| Alston et al. | Action of Penicillin on Leptospira | |
| Elias et al. | Blood, urine and fecal levels of streptomycin in the treatment of human infections of E. typhosa | |
| Jariwalla et al. | Infective endocarditis complicating psittacosis: response to rifampicin. | |
| US4472378A (en) | Live vaccine for the prevention of salmonellosis in water fowl, a process for making and applying the same | |
| Schwab et al. | Production of generalized Shwartzman reaction with group A streptococcal factors. | |
| KR0169982B1 (ko) | 피부염 치료용 약제 | |
| CN101618213B (zh) | 麻疹腮腺炎乙型脑炎联合减毒活疫苗及其制备方法 | |
| Hobby et al. | An evaluation of chemotherapeutic agents in the control of experimental infections due to Mycobacterium leprae murium | |
| EP1609473A1 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria | |
| Foley et al. | The effect of stilbestrol on experimental streptococcal infection in mice | |
| JPS5946493B2 (ja) | 異種死菌体混合物を有効成分とする抗腫瘍剤 | |
| US3197373A (en) | Immunological agent | |
| CN111978394B (zh) | 用于covid-19患者特异性免疫疗法的多克隆制剂的制备方法 | |
| Miller et al. | Studies on the action of penicillin: VI. Further observations on the development of penicillin resistance by Meningococcus in vitro |